cefdinir (CFDN)

02/01/2015 - "Given these preliminary results, a fully powered study is warranted to explore the efficacy of cefdinir as a therapeutic tool for new-onset pediatric neuropsychiatric symptoms, particularly those that appear to be precipitated by infection."
04/01/1997 - "Cefdinir appears to be an effective and well-tolerated agent for the treatment of uncomplicated skin and skin structure infections in pediatric patients."
01/01/1994 - "In vivo therapeutic efficacy of cefdinir (FK482), a new oral cephalosporin, against Staphylococcus aureus and Haemophilus influenzae in mouse infection models."
10/01/1991 - "CFDN was effective in 94% of 32 cases with respiratory tract, middle ear, urinary tract or skin structure infections. "
05/01/2004 - "Cefdinir, an extended spectrum, third-generation cephalosporin is a safe and effective means of treating skin infections caused by these organisms, as well as many gram-negative pathogens. "

05/01/1998 - "Five-day treatment with cefdinir is safe and effective therapy for GABHS pharyngitis. "
11/01/1999 - "This multicenter, randomized, controlled, double-masked study assessed the tolerability and efficacy of 2 dosing regimens of cefdinir in the treatment of pharyngitis due to GABHS. "
11/01/1999 - "Cefdinir Pharyngitis Study Group."
09/01/1999 - "This multicenter, randomized, controlled, investigator-masked study was performed to assess the efficacy and tolerability of cefdinir for the treatment of streptococcal pharyngitis. "
05/01/1998 - "Cefdinir Pharyngitis Study Group."

12/01/2000 - "To examine the microbiologic and clinical efficacy of a 5-day course of cefdinir in the treatment of tympanocentesis-documented acute otitis media (AOM). "
05/01/2008 - "Three weeks later, he again received cefdinir for recurrent otitis media. "
12/01/2000 - "Five-day twice daily cefdinir therapy for acute otitis media: microbiologic and clinical efficacy."
03/01/2006 - "A multicenter, open label, double tympanocentesis study of high dose cefdinir in children with acute otitis media at high risk of persistent or recurrent infection."
03/01/2006 - "Because the current cefdinir dosage of 14 mg/kg/d is approved for treatment of acute otitis media caused by penicillin-susceptible Streptococcus pneumoniae, we hypothesized that a 25-mg/kg dose given daily would be more effective for nonsusceptible S. "

11/17/2004 - "cefdinir is safe and effective, shorten the course of treatment in the treatment of mild to moderate bacterial community acquired pneumonia."
07/01/1997 - "These results indicate that cefdinir is effective and safe in the treatment of patients with pneumonia."
11/17/2004 - "To evaluate the efficacy and safety of cefdinir in the treatment of patients with mild to moderate bacterial community acquired pneumonia (CAP). "
10/01/2001 - "Twice-daily administration is likely the more appropriate cefdinir dosing strategy for the treatment of community-acquired pneumonia."
10/01/1991 - "Among the patients with pneumonia, CFDN 20 mg/kg/day dose group showed better clinical responses and better bacteriological effects against H. "

06/01/2000 - "These results indicate that a five-day regimen of cefdinir is effective and safe for the treatment of patients with acute exacerbations of chronic bronchitis."
06/01/2000 - "To compare the efficacy and safety of five-day cefdinir treatment with seven-day loracarbef treatment in patients with acute exacerbations of chronic bronchitis, 586 patients were enrolled in a multicentre, randomised, double-blind trial. "
06/01/2000 - "Patients with acute exacerbations of chronic bronchitis were treated with cefdinir 300 mg bd for 5 days or cefprozil 500 mg bd for 10 days in a prospective, randomized, double-blind, multicentre study. "
01/01/2000 - "International study comparing cefdinir and cefuroxime axetil in the treatment of patients with acute exacerbation of chronic bronchitis."
06/01/2000 - "A comparison of a five-day regimen of cefdinir with a seven-day regimen of loracarbef for the treatment of acute exacerbations of chronic bronchitis."